CHM.AX up 50% pre-market 07 Jan 2026: volume 18.91M signals active trading ahead
CHM.AX stock opened pre-market on 07 Jan 2026 with a 50.00% intraday move to A$0.003, driven by heavy flow of 18,910,051 shares. This spike lifted volume to 2.22x the average and moved the price off a A$0.002 open. Traders should note the trade is concentrated and the company remains a clinical-stage biotechnology name listed on the ASX in Australia, with ongoing phase I trials that underpin longer-term value.
Market snapshot and trade details for CHM.AX stock
CHM.AX stock traded between A$0.002 and A$0.003 today on ASX with market capitalisation about A$12,326,400. Volume hit 18,910,051 versus an average of 8,536,158, giving a relative volume of 2.22. The 50% move follows a previous close of A$0.002 and a 52-week range of A$0.002–A$0.009.
Why volume surged and event context
The surge looks driven by short-term liquidity and headline scanning rather than a company update. News aggregators listed CHM.AX in top movers across market pages today, drawing momentum traders. Heavy turnover often precedes volatility for micro-cap biotech names with thin free float.
Earnings, financials and fundamentals for CHM.AX stock
Most recent fiscal data show negative earnings and cash burn typical of clinical-stage biotech. Reported EPS was -0.022 versus an estimate of -0.02857, and revenue change was -1,756,393.00 AUD in the last fiscal period. Key ratios include PB 2.57, price-to-sales 1.35, current ratio about 0.72, and negative operating cash flow per share of -0.00293.
Technicals, valuation and Meyka AI grade for CHM.AX stock
Technical indicators show neutral momentum with RSI 50.22 and ADX 19.67, consistent with a non-trending market. Meyka AI rates CHM.AX with a score out of 100: 66.03 | Grade B | HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Price averages sit near A$0.00305 (50-day) and A$0.00384 (200-day).
Analyst context, forecasts and realistic price targets
External analyst consensus is limited for this micro-cap. Meyka AI’s internal model suggests a near-term quarterly reference target of A$0.010, and a conservative 12-month scenario of A$0.020 if clinical catalysts materialise. Those targets compare with the current A$0.003 price and assume successful trial readouts or partnering news.
Risks, trading setup and short-term strategy
CHM.AX carries typical biotech risks: clinical failure, dilution from capital raises, and low liquidity. With the current high volume, traders should size positions small and set tight risk controls. For short-term traders, watch daily VWAP and book limit orders. For investors, monitor upcoming earnings and the next earnings announcement date on 26 Feb 2026.
Final Thoughts
Key takeaways for CHM.AX stock: the ASX-listed biotech jumped 50.00% pre-market to A$0.003 on 07 Jan 2026, led by unusually high volume of 18,910,051 shares. Fundamentals show negative EPS and ongoing cash usage, consistent with a clinical-stage developer. Meyka AI’s forecast model projects a quarterly reference of A$0.010, implying +233.33% versus the current price of A$0.003, and a cautious 12-month scenario of A$0.020. These forecasts are model-based projections and not guarantees. The Meyka AI grade is 66.03 (B, HOLD) and factors S&P 500 comparison, sector performance, financial growth, metrics, and analyst signals. Traders should treat today’s move as high-volume speculation unless confirmed by company news or clinical milestones. Use strict position sizing and confirm liquidity before entering larger trades. For further real-time data, see the company page on Meyka AI and market quotes on Yahoo Finance CHM.AX quote and CHM.AX news. Meyka AI is the AI-powered market analysis platform behind the forecast model.
FAQs
The jump reflects heavy trading and headline visibility, not a confirmed company announcement. Volume reached **18.91M** and pushed the price from **A$0.002** to **A$0.003** on ASX, attracting momentum traders.
Monitor price-to-sales **1.35**, price-to-book **2.57**, current ratio **0.72**, and cash per share **A$0.00340**. These show thin liquidity and typical early-stage biotech metrics.
Yes. Meyka AI’s forecast model projects a quarterly reference of **A$0.010**, implying roughly **+233.33%** from **A$0.003** today. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
